FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rolf Stahel

Research Profile

Disorders

Anatomy

Chemicals & Drugs

Procedures

Living Beings

Mouse

Concepts & Ideas

Neoplasm Staging

Co-author Network

Publications

TOP 3
Harald Nater; Verena Niggemeier; Rolf A Stahel; Daniel Franzen
[In Process Citation].
Yandong Shi; Alex Soltermann; Rolf A Stahel; Svenja Thies; Walter Weder; Ubiratan Moura; Isabelle Opitz; Hubert Rehrauer; Emanuela Felley-Bosco
Role of hedgehog signaling in malignant pleural mesothelioma.
Walter Weder; Paul Baas; Urania Dafni; Marc De Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; Rolf A Stahel; David J Sugarbaker; nico van zandwijk
The MARS feasibility trial: conclusions not supported by data.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rolf Stahel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Harald Nater; Verena Niggemeier; Rolf A Stahel; Daniel Franzen
[In Process Citation].
Praxis 2013;102(9):503-12.
2012: Yandong Shi; Alex Soltermann; Rolf A Stahel; Svenja Thies; Walter Weder; Ubiratan Moura; Isabelle Opitz; Hubert Rehrauer; Emanuela Felley-Bosco
Role of hedgehog signaling in malignant pleural mesothelioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(17):4646-56.
2011: Walter Weder; Paul Baas; Urania Dafni; Marc De Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; Rolf A Stahel; David J Sugarbaker; nico van zandwijk
The MARS feasibility trial: conclusions not supported by data.
The lancet oncology 2011;12(12):1093-4; author reply 1094-5.
2011: Philip A Knobel; Ilya N Kotov; Emanuela Felley-Bosco; Rolf A Stahel; Thomas M Marti
Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells.
Neoplasia (New York, N.Y.) 2011;13(10):961-70.
2011: Thomas Frauenfelder; R P Götti; B Seifert; Rolf A Stahel; Michaela Tutic; Walter Weder; Isabelle Opitz
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2011;38(1):162-8.
2011: Stefanie Arbogast; Silvia Behnke; Isabelle Opitz; Rolf A Stahel; Burkhardt Seifert; Walter Weder; Holger Moch; Alex Soltermann
Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2011;19(2):99-105.
2011: Roy Sidi; Giulia Pasello; Isabelle Opitz; Alex Soltermann; Michaela Tutic; Hubert Rehrauer; Walter Weder; Rolf A Stahel; Emanuela Felley-Bosco
Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.
European journal of cancer (Oxford, England : 1990) 2011;47(2):326-32.
2011: Panagiotis Samaras; Marcel Blickenstorfer; Raffaele Daniele Siciliano; Sarah R Haile; Elefteri M Buset; Ulf Petrausch; Axel Mischo; Hanspeter Honegger; Urs Schanz; Georg Stussi; Rolf A Stahel; Alexander Knuth; Frank Stenner-Liewen; Christoph Renner
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.
Annals of hematology 2011;90(1):89-94.
2010: Rolf A Stahel; Walter Weder; Y Lievens; E Felip
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 5():v126-8.
2010: Panagiotis Samaras; Elefteri M Buset; Raffaele Daniele Siciliano; Sarah R Haile; Ulf Petrausch; Axel Mischo; Hanspeter Honegger; Bernhard C Pestalozzi; Urs Schanz; Georg Stussi; Rolf A Stahel; Alexander Knuth; Christoph Renner; Frank Stenner-Liewen
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
Oncology 2010;79(1-2):93-7.
2009: Rolf A Stahel; Walter Weder; E Felip
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():73-5.
2009: Claudio Thurneysen; Isabelle Opitz; Stefanie Kurtz; Walter Weder; Rolf A Stahel; Emanuela Felley-Bosco
Functional inactivation of NF2/merlin in human mesothelioma.
Lung cancer (Amsterdam, Netherlands) 2009;64(2):140-7.
2009: Rolf A Stahel; Emanuela Felley-Bosco; Isabelle Opitz; Walter Weder
Malignant pleural mesothelioma.
Future oncology (London, England) 2009;5(3):391-402.
2009: Rolf A Stahel; Walter Weder
Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?
Current opinion in oncology 2009;21(2):124-30.
2008: Rolf A Stahel
Educational book of the 33rd ESMO Congress Stockholm, Sweden 12-16 September 2008. Introduction.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 7():vii22.
2008: Karin Ribi; Jürg Bernhard; Jan C Schuller; Walter Weder; Stephan Bodis; Markus Jörger; Daniel Betticher; Ralph A Schmid; Roger Stupp; Hans-Beat Ris; Rolf A Stahel
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
Lung cancer (Amsterdam, Netherlands) 2008;61(3):398-404.
2008: Armando Santoro; Mary E O'Brien; Rolf A Stahel; Kristiaan Nackaerts; Paul Baas; Meinolf Karthaus; Wilfried Eberhardt; Luis Paz-Ares; Stein Sundstrom; Yushan Liu; Veronique Ripoche; Johannes Blatter; Carla M Visseren-Grul; Christian Manegold
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(7):756-63.
2008: Rolf A Stahel; Walter Weder; E Felip
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 2():ii43-4.
2007: Annemarie Ziegler; Christian A Seemayer; Marc Hinterberger; Peter Vogt; Colette Bigosch; Oliver Gautschi; Luigi Tornillo; Daniel C Betticher; Holger Moch; Rolf A Stahel
Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results.
Lung cancer (Amsterdam, Netherlands) 2007;57(3):282-91.
2007: Rolf A Stahel
Adenocarcinoma, a molecular perspective.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 9():ix147-9.
2007: Walter Weder; Rolf A Stahel; Jürg Bernhard; Stephan Bodis; Peter Vogt; Pierluigi Ballabeni; Didier Lardinois; Daniel C Betticher; R Schmid; Roger Stupp; Hans-Beat Ris; Monika Jermann; Walter Mingrone; Arnaud D Roth; A Spiliopoulos
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(7):1196-202.
2007: Larisa L Belyanskaya; Thomas Marti; Sally Hopkins-Donaldson; Stefanie Kurtz; Emanuela Felley-Bosco; Rolf A Stahel
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
Molecular cancer 2007;6():66.
2006: Rolf A Stahel
Non-small cell lung cancer: second-line and beyond.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x97-100.
2006: Monika Jermann; Rolf A Stahel; Marc Salzberg; Thomas Cerny; Markus Joerger; Silke Gillessen; Rudolf Morant; Fritz Egli; Kaspar Rhyner; Jean A Bauer; Miklos Pless
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Cancer chemotherapy and pharmacology 2006;57(4):533-9.
2006: Oliver Gautschi; Barbara Hugli; Annemarie Ziegler; Colette Bigosch; Naomi L Bowers; Daniel Ratschiller; Monika Jermann; Rolf A Stahel; Jim Heighway; Daniel C Betticher
Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Lung cancer (Amsterdam, Netherlands) 2006;51(3):303-11.
2005: Didier Lardinois; Walter Weder; Marina Roudas; Gustav K von Schulthess; Michaela Tutic; Holger Moch; Rolf A Stahel; Hans C Steinert
Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):6846-53.
2005: A Paula Simões-Wüst; Brigitte Sigrist; Larisa L Belyanskaya; Sally Hopkins-Donaldson; Rolf A Stahel; Uwe Zangemeister-Wittke
DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells.
Journal of neuro-oncology 2005;72(1):29-34.
2005: LM Jost; Rolf A Stahel
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 1():i60-1.
2005: LM Jost; O Kloke; Rolf A Stahel
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 1():i58-9.
2005: LM Jost; Rolf A Stahel
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 1():i54-5.
2005: B Simonsson; O Kloke; Rolf A Stahel
ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 1():i52-3.
2004: Oliver Gautschi; Colette Bigosch; Barbara Huegli; Monika Jermann; Arthur Marx; Eveline Chassé; Daniel Ratschiller; Walter Weder; Markus Joerger; Daniel C Betticher; Rolf A Stahel; Annemarie Ziegler
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(20):4157-64.
2004: Walter Weder; Peter Kestenholz; Christian Taverna; Stephan Bodis; Didier Lardinois; Monika Jerman; Rolf A Stahel
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(17):3451-7.
2004: Andreas Trojan; Mirjana Urosevic-Maiwald; Reinhard Dummer; Robin Giger; Walter Weder; Rolf A Stahel
Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;44(2):143-7.
2004: Monika Jermann; LM Jost; Christian Taverna; Emanuel Jacky; Hanspeter Honegger; Daniel C Betticher; Fritz Egli; Th Kroner; Rolf A Stahel
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(3):511-6.
2004: A Paula Simões-Wüst; Sally Hopkins-Donaldson; Brigitte Sigrist; Larisa L Belyanskaya; Rolf A Stahel; Uwe Zangemeister-Wittke
A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
Oligonucleotides 2004;14(3):199-209.
2004: Andreas Trojan; Helen I Joller-Jemelka; Rolf A Stahel; Emanuel Jacky; Martin Hersberger
False-positive human serum chorionic gonadotropin in a patient with a history of germ cell cancer.
Oncology 2004;66(4):336-8.
2004: Konstantin Dedes; Thomas D Szucs; Stephan Bodis; Markus Joerger; Adam Lowy; Erich W Russi; Hans C Steinert; Walter Weder; Rolf A Stahel
Management and costs of treating lung cancer patients in a university hospital.
PharmacoEconomics 2004;22(7):435-44.
2003: Sally Hopkins-Donaldson; Richard Cathomas; A Paula Simões-Wüst; Stefanie Kurtz; Larisa L Belyanskaya; Rolf A Stahel; Uwe Zangemeister-Wittke; Larisa Belyanskya
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
International journal of cancer. Journal international du cancer 2003;106(2):160-6.
2003: Andreas Trojan; Mirjana Urosevic-Maiwald; Jörg Hummerjohann; Robin Giger; Urs Schanz; Rolf A Stahel
Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(1):41-6.
2003: Oliver Gautschi; Uwe Zangemeister-Wittke; Rolf A Stahel
Comment on "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer", by C. M. Rudin et al. (Ann Oncol 2002; 13: 539-545).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(1):170.
2002: A Paula Simões-Wüst; Thomas Schürpf; Jonathan Hall; Rolf A Stahel; Uwe Zangemeister-Wittke
Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Breast cancer research and treatment 2002;76(2):157-66.
2002: Robert A Olie; Jonathan Hall; Francois Natt; Rolf A Stahel; Uwe Zangemeister-Wittke
Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide.
Biochimica et biophysica acta 2002;1576(1-2):101-9.
2002: Andreas Trojan; Mirjana Urosevic-Maiwald; Reinhard Dummer; Frank O Nestle; Rolf A Stahel
Real-time polymerase chain reaction monitoring of epithelial cell adhesion molecule-induced T-cell stimulation in patients with lung cancer and healthy individuals using LightCycler technology.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):264-8.
2002: Andreas Trojan; Adrian Tun-Kyi; Bernhard Odermatt; Frank O Nestle; Rolf A Stahel
Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors.
Lung cancer (Amsterdam, Netherlands) 2002;36(2):151-8.
2002: Robert A Olie; Christoph Hafner; Renzo Küttel; Brigitte Sigrist; Jörg Willers; Reinhard Dummer; Jonathan Hall; Rolf A Stahel; Uwe Zangemeister-Wittke
Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
The Journal of investigative dermatology 2002;118(3):505-12.
2001: Mirjana Urosevic-Maiwald; Michael O Kurrer; Jivko Kamarashev; Beatrix Mueller; Walter Weder; Guenter Burg; Rolf A Stahel; Reinhard Dummer; Andreas Trojan
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production.
The American journal of pathology 2001;159(3):817-24.
2001: Andreas Himmelmann; Oliver Gautschi; M Nawrath; U Bolliger; J Fehr; Rolf A Stahel
Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells.
British journal of haematology 2001;114(2):400-5.
2001: Andreas Trojan; Mathias Witzens; Joachim L Schultze; Robert H Vonderheide; Sabine Harig; Angela M Krackhardt; Rolf A Stahel; John G Gribben
Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.
Cancer research 2001;61(12):4761-5.
2001: Oliver Gautschi; S Tschopp; Robert A Olie; Siân H Leech; A Paula Simões-Wüst; A Ziegler; B Baumann; B Odermatt; Jonathan Hall; Rolf A Stahel; Uwe Zangemeister-Wittke
Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
Journal of the National Cancer Institute 2001;93(6):463-71.
2001: Gabriella Pichert; Shu-Fang Hsu Schmitz; Urs Hess; Thomas Cerny; Sergio B Cogliatti; Daniel C Betticher; Roger Stupp; D Schmitter; Rolf A Stahel; Michele Ghielmini
Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells.
Clinical lymphoma 2001;1(4):293-7.
2000: Gabriella Pichert; Rolf A Stahel
Organizing cancer genetics programs: the Swiss model.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(21 Suppl):65S-9S.
2000: A I Ernst; A Soltermann; J A Sigrist; L Widmer; Susan Gasser; Rolf A Stahel
Ectopic expression of human topoisomerase IIalpha fragments and etoposide resistance in mammalian cells.
International journal of cancer. Journal international du cancer 2000;88(1):99-107.
2000: A Paula Simões-Wüst; Robert A Olie; Oliver Gautschi; Siân H Leech; Robert Häner; Jonathan Hall; Doriano Fabbro; Rolf A Stahel; Uwe Zangemeister-Wittke
Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells.
International journal of cancer. Journal international du cancer 2000;87(4):582-90.
2000: G Tscherry; Emanuel Jacky; LM Jost; Rolf A Stahel
Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
Oncology 2000;59(2):110-7.
2000: Uwe Zangemeister-Wittke; Siân H Leech; Robert A Olie; A Paula Simões-Wüst; Oliver Gautschi; GH Luedke; Francois Natt; Robert Häner; P Martin; Jonathan Hall; C M Nalin; Rolf A Stahel
A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2547-55.
2000: Robert A Olie; A Paula Simões-Wüst; B Baumann; Siân H Leech; Doriano Fabbro; Rolf A Stahel; Uwe Zangemeister-Wittke
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.
Cancer research 2000;60(11):2805-9.
2000: Siân H Leech; Robert A Olie; Oliver Gautschi; A Paula Simões-Wüst; S Tschopp; Robert Häner; Jonathan Hall; Rolf A Stahel; Uwe Zangemeister-Wittke
Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment.
International journal of cancer. Journal international du cancer 2000;86(4):570-6.
2000: LM Jost; Hanspeter Honegger; Rolf A Stahel
[High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
Schweizerische medizinische Wochenschrift 2000;130(3):60-9.
1999: A Soltermann; A Ernst; Didier Leroy; Rolf A Stahel; Susan Gasser
The cytochrome b5 tail anchors and stabilizes subdomains of human DNA topoisomerase II alpha in the cytoplasm of retrovirally infected mammalian cells.
Experimental cell research 1999;249(2):308-19.
1999: Rolf A Stahel; LM Jost; Th Kroner; Corina Dommann-Scherrer; Robert Maurer; Christoph Glanzmann; Emanuel Jacky; Gabriella Pichert; Bernhard C Pestalozzi; B Marincek; C Sauter; Hanspeter Honegger
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission.
British journal of haematology 1999;104(4):763-9.
1998: M K Pass; G Quintini; J A Zarn; S M Zimmermann; J A Sigrist; Rolf A Stahel
The 5'-flanking region of human CD24 gene has cell-type-specific promoter activity in small-cell lung cancer.
International journal of cancer. Journal international du cancer 1998;78(4):496-502.
1998: Uwe Zangemeister-Wittke; T Schenker; GH Luedke; Rolf A Stahel
Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
British journal of cancer 1998;78(8):1035-42.
1998: Gabriella Pichert; D Schmitter; L Widmer; LM Jost; M O Kurrer; R Maurer; Rolf A Stahel
Selection and immunomagnetic purging of peripheral blood CD34+ cells for autologous transplantation in B-cell non-Hodgkin's lymphomas.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):51-4.
1997: D Schmitter; M Koss; E Niederer; Rolf A Stahel; Gabriella Pichert
T-cell derived cytokines co-stimulate proliferation of CD40-activated germinal centre as well as follicular lymphoma cells.
Hematological oncology 1997;15(4):197-207.
1997: LM Jost; L Widmer; Hanspeter Honegger; Rolf A Stahel
Index of pretreatment intensity predicts outcome of high-dose chemotherapy and autologous progenitor cell transplantation in chemosensitive relapse of Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(8):785-90.
1997: A Ziegler; GH Luedke; Doriano Fabbro; K H Altmann; Rolf A Stahel; Uwe Zangemeister-Wittke
Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
Journal of the National Cancer Institute 1997;89(14):1027-36.
1997: Rolf A Stahel; LM Jost; Hanspeter Honegger; E Betts; M E Goebel; A Nagler
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1730-5.
1996: L Widmer; Gabriella Pichert; LM Jost; Rolf A Stahel
Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
Blood 1996;88(8):3166-75.
1996: J A Zarn; S M Zimmermann; M K Pass; Robert Waibel; Rolf A Stahel
Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line.
Biochemical and biophysical research communications 1996;225(2):384-91.
1996: Roland Schnell; A A Katouzi; C Linnartz; G Schoen; S Drillich; Martin-Leo Hansmann; D Schiefer; Stefan Barth; Uwe Zangemeister-Wittke; Rolf A Stahel; Volker Diehl; Andreas Engert
Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
International journal of cancer. Journal international du cancer 1996;66(4):526-31.
1996: B A Froesch; Rolf A Stahel; Uwe Zangemeister-Wittke
Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells.
Cancer immunology, immunotherapy : CII 1996;42(1):55-63.
1995: E Weber; D Schmitter; H Resch; J A Zarn; Robert Waibel; M Mabry; P Huguenin; Rolf A Stahel
Radiation studies on B cell differentiation marker CD24/SCLC Cluster-4 antigen expressing and non-expressing lung cancer cell lines and mouse fibroblasts.
International journal of radiation biology 1995;68(2):205-13.
1995: LM Jost; Emanuel Jacky; C Dommann-Scherrer; Hanspeter Honegger; R Maurer; C Sauter; Rolf A Stahel
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(5):445-51.
1995: Rolf A Stahel; LM Jost; Gabriella Pichert; L Widmer
High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas.
Cancer treatment reviews 1995;21(1):3-32.
1995: J A Zarn; David G Jackson; M V Bell; T Jones; E Weber; Denise Sheer; Robert Waibel; Rolf A Stahel
The small cell lung cancer antigen cluster-4 and the leukocyte antigen CD24 are allelic isoforms of the same gene (CD24) on chromosome band 6q21.
Cytogenetics and cell genetics 1995;70(1-2):119-25.
1994: I A Mórocz; D Schmitter; B Lauber; Rolf A Stahel
Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway.
British journal of cancer 1994;70(5):850-6.
1994: Rolf A Stahel
Antigens, receptors and dominant oncogenes and the prognosis of non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1994;11 Suppl 3():S31-8.
1994: Rolf A Stahel; LM Jost; T Cerny; Gabriella Pichert; Hanspeter Honegger; A Tobler; Emanuel Jacky; M Fey; E Platzer
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(9):1931-8.
1994: Rolf A Stahel; W R Gilks; T Schenker
Antigens of lung cancer: results of the Third International Workshop on Lung Tumor and Differentiation Antigens.
Journal of the National Cancer Institute 1994;86(9):669-72.
1994: Rolf A Stahel
Biology of lung cancer.
Lung cancer (Amsterdam, Netherlands) 1994;10 Suppl 1():S59-65.
1994: Rolf A Stahel; W R Gilks; H P Lehmann; T Schenker
Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1994;8():6-26.
1994: A Smith; Uwe Zangemeister-Wittke; Robert Waibel; T Schenker; P August Schubiger; Rolf A Stahel
A comparison of 67Cu- and 131I-labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancer.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1994;8():43-8.
1994: W R Gilks; Rolf A Stahel; N Walker; T Schenker
Statistical analysis of data from the Third International IALSC Workshop on Lung Tumor and Differentiation Antigens.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1994;8():2-5.
1994: H P Lehmann; E Weber; T Schenker; K Mattson; Robert Waibel; Rolf A Stahel
Immunological evidence for co-expression of cluster-5 and cluster-5A small cell lung cancer antigen on a single molecule.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1994;8():76-80.
1994: David G Jackson; T Schenker; Robert Waibel; John I Bell; Rolf A Stahel
Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1994;8():110-5.
1994: Uwe Zangemeister-Wittke; A R Collinson; B Frösch; Robert Waibel; T Schenker; Rolf A Stahel
Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer.
British journal of cancer 1994;69(1):32-9.
1993: E Weber; H P Lehmann; Annette G Beck-Sickinger; E J Wawrzynczak; Robert Waibel; G Folkers; Rolf A Stahel
Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline.
Clinical and experimental immunology 1993;93(2):279-85.
1993: Uwe Zangemeister-Wittke; A R Collinson; I Fisch; R M Jones; Robert Waibel; H P Lehman; Rolf A Stahel
Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer.
International journal of cancer. Journal international du cancer 1993;54(6):1028-35.
1993: Robert Waibel; M Mannhart; C J O'Hara; C Brocklehurst; Uwe Zangemeister-Wittke; T Schenker; H P Lehmann; E Weber; Rolf A Stahel
Monoclonal antibody SEN7 recognizes a new epitope on the neural cell adhesion molecule present on small cell lung cancer but not on lymphocytes.
Cancer research 1993;53(12):2840-5.
1993: LM Jost; Gabriella Pichert; M Reichlin; E Müller; Emanuel Jacky; Hanspeter Honegger; Jürg Gmür; Rolf A Stahel
[5 years of dosage intensification and autologous bone marrow or peripheral stem cell transfusion in malignant lymphoma with a high risk of recurrence].
Schweizerische medizinische Wochenschrift 1993;123(18):932-40.
1993: U Müller; Rolf A Stahel
Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(5):399-402.
1993: Uwe Zangemeister-Wittke; H P Lehmann; Robert Waibel; E J Wawrzynczak; Rolf A Stahel
Action of a CD24-specific deglycosylated ricin-A-chain immunotoxin in conventional and novel models of small-cell-lung-cancer xenograft.
International journal of cancer. Journal international du cancer 1993;53(3):521-8.
1993: I A Mórocz; B Lauber; D Schmitter; Rolf A Stahel
In vitro effect of suramin on lung tumour cells.
European journal of cancer (Oxford, England : 1990) 1993;29A(2):245-7.
1992: E Schreiber; A Himmelmann; Ursula Malipiero; A Tobler; Rolf A Stahel; Adriano Fontana
Human small cell lung cancer expresses the octamer DNA-binding and nervous system-specific transcription factor N-Oct 3 (brain-2).
Cancer research 1992;52(21):6121-4.
1992: D Jackson; Robert Waibel; E Weber; J Bell; Rolf A Stahel
CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas.
Cancer research 1992;52(19):5264-70.
1992: E J Derbyshire; R V Henry; Rolf A Stahel; E J Wawrzynczak
Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines.
British journal of cancer 1992;66(3):444-51.
1992: E J Derbyshire; Rolf A Stahel; E J Wawrzynczak
Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule.
Clinical and experimental immunology 1992;89(3):336-40.
1992: Gabriella Pichert; J Peters; Rolf A Stahel; C Dommann; R Joss; J O Gebbers; T Kroner; H Sulser; Hanspeter Honegger; R Maurer
Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(8):645-9.
1992: E J Wawrzynczak; Uwe Zangemeister-Wittke; Robert Waibel; R V Henry; G D Parnell; A J Cumber; M Jones; Rolf A Stahel
Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.
British journal of cancer 1992;66(2):361-6.
1992: D Schmitter; B Lauber; B Fagg; Rolf A Stahel
Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature.
International journal of cancer. Journal international du cancer 1992;51(2):296-301.
1992: B Lauber; M Leuthold; D Schmitter; J Cano-Santos; Robert Waibel; Rolf A Stahel
An autocrine mitogenic activity produced by a pleural human mesothelioma cell line.
International journal of cancer. Journal international du cancer 1992;50(6):943-50.
1992: Rolf A Stahel; H Lacroix; J P Sculier; R Morant; J Richner; E Janzek; H Loibner; H Blythman
Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(4):319-20.
1992: H P Lehmann; C Zwicky; Robert Waibel; Rolf A Stahel
Tumor-antigen-specific humoral immune response of animals to anti-idiotypic antibodies and comparative serological analysis of patients with small-cell lung carcinoma.
International journal of cancer. Journal international du cancer 1992;50(1):86-92.
1992: E J Derbyshire; Rolf A Stahel; E J Wawrzynczak
Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer.
Cancer immunology, immunotherapy : CII 1992;35(6):417-20.
1991: A Smith; Robert Waibel; Rolf A Stahel
Selective immunotherapy of small cell cancer xenografts using 131I-labelled SWA11 antibody.
British journal of cancer 1991;64(2):263-6.
1991: E J Wawrzynczak; E J Derbyshire; R V Henry; G D Parnell; A Smith; Robert Waibel; Rolf A Stahel
Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.
The British journal of cancer. Supplement 1991;14():71-3.
1991: C Zwicky; Rolf A Stahel; H Jaksche; Robert Waibel; H P Lehmann; H Loibner
Polyclonal anti-idiotypic antibodies mimicking the small cell lung carcinoma antigen cluster-5A interact with a panel of antibodies and induce specific immune response in animals.
The British journal of cancer. Supplement 1991;14():67-70.
1991: L Austin Doyle; M Mabry; Rolf A Stahel; Robert Waibel; L H Goldstein
Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines.
The British journal of cancer. Supplement 1991;14():39-42.
1991: Robert Waibel; C J O'Hara; Rolf A Stahel
Monoclonal antibodies defining the cluster-5A small cell lung carcinoma antigen.
The British journal of cancer. Supplement 1991;14():29-32.
1991: Gabriella Pichert; LM Jost; Walter Fierz; Rolf A Stahel
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
British journal of cancer 1991;63(2):287-92.
1990: LM Jost; Gabriella Pichert; Rolf A Stahel
Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(6):439-42.
1990: E J Wawrzynczak; E J Derbyshire; R V Henry; G D Parnell; A Smith; Robert Waibel; Rolf A Stahel
Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.
British journal of cancer 1990;62(3):410-4.
1990: Gabriella Pichert; LM Jost; L Zöbeli; B Odermatt; G Pedia; Rolf A Stahel
Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
British journal of cancer 1990;62(1):100-4.
1990: P Groscurth; S Diener; Rolf A Stahel; L Jost; D Kägi; Hans Hengartner
Morphologic analysis of human lymphokine-activated killer (LAK) cells.
International journal of cancer. Journal international du cancer 1990;45(4):694-704.
1990: A Smith; P Groscurth; Robert Waibel; G Westera; Rolf A Stahel
Imaging and therapy of small cell carcinoma xenografts using 131I-labeled monoclonal antibody SWA11.
Cancer research 1990;50(3 Suppl):980s-984s.
1989: Rolf A Stahel; LM Jost; J Burger; Hanspeter Honegger; G P Brun del Re; Jürg Gmür
[High-dosage chemo-radiotherapy with autologous bone marrow transfusion in malignant lymphoma: indications and personal experience].
Schweizerische medizinische Wochenschrift 1989;119(25):911-7.
1989: Rolf A Stahel; J P Sculier; LM Jost; A Delforge; D Bron; Jürg Gmür; O Oelz; C Sauter; P Stryckmans; J Klastersky
Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors.
European journal of cancer & clinical oncology 1989;25(6):965-72.
1989: A Barth; Robert Waibel; Rolf A Stahel
Monoclonal anti-idiotypic antibody mimicking a tumor-associated sialoglycoprotein antigen induces humoral immune response against human small-cell lung carcinoma.
International journal of cancer. Journal international du cancer 1989;43(5):896-900.
1989: A Smith; Robert Waibel; G Westera; A Martin; A T Zimmerman; Rolf A Stahel
Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11.
British journal of cancer 1989;59(2):174-8.
1988: Robert Waibel; C J O'Hara; A Smith; Rolf A Stahel
Tumor-associated membrane sialoglycoprotein on human small cell lung carcinoma identified by the IgG2a monoclonal antibody SWA20.
Cancer research 1988;48(15):4318-23.
1988: Rolf A Stahel; C J O'Hara; Robert Waibel; A Martin
Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma.
International journal of cancer. Journal international du cancer 1988;41(2):218-23.
1987: Robert Waibel; C J O'Hara; Rolf A Stahel
Characterization of an epithelial and a tumor-associated human small cell lung carcinoma glycoprotein antigen.
Cancer research 1987;47(14):3766-70.
1987: Rolf A Stahel; G Martz
Prognostic and diagnostic usefulness of serum markers in lung cancer.
European journal of cancer & clinical oncology 1987;23(7):893-4.
1986: Rolf A Stahel; C J O'Hara; M Mabry; Robert Waibel; K Sabbath; J A Speak; S D Bernal
Cytotoxic murine monoclonal antibody LAM8 with specificity for human small cell carcinoma of the lung.
Cancer research 1986;46(4 Pt 2):2077-84.
1985: Rolf A Stahel; M Mabry; K Sabbath; J A Speak; S D Bernal
Selective cytotoxicity of murine monoclonal antibody LAM2 against human small-cell carcinoma in the presence of human complement: possible use for in vitro elimination of tumor cells from bone marrow.
International journal of cancer. Journal international du cancer 1985;35(5):587-92.
1985: M Mabry; J A Speak; James D Griffin; Rolf A Stahel; S D Bernal
Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung.
The Journal of clinical investigation 1985;75(5):1690-5.
1985: Rolf A Stahel; M Mabry; Arthur T Skarin; J Speak; S D Bernal
Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(4):455-61.
1985: S D Bernal; M Mabry; Rolf A Stahel; James D Griffin; J A Speak
Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung.
Cancer research 1985;45(3):1026-32.
1985: Rolf A Stahel; J A Speak; S D Bernal
Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human lung small-cell carcinoma and squamous-cell carcinomas.
International journal of cancer. Journal international du cancer 1985;35(1):11-7.